Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma have?
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma has 780 citations in the OpenAlex counts ScholarIQ stores.
When was Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma published?
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma has 2019 year in the ScholarIQ index.
What is the open-access status of Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma?
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma has hybrid oa status in the ScholarIQ index.
What is the DOI of Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma?
The DOI for Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma is on the source record.
What is the PMID of Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma?
The PMID for Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma is on the source record.
What is the OpenAlex record for Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma?
The OpenAlex for Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma is on the source record.